CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: GPR157 (ImmuneEditome ID:80045)

1. Gene summary of enriched editing regions for GPR157

check button Gene summary
Gene informationGene symbol

GPR157

Gene ID

80045

GeneSynonyms-
GeneCytomap

1p36.22

GeneTypeprotein-coding
GeneDescriptionG-protein coupled receptor 157|probable G-protein coupled receptor 157
GeneModificationdate20230329
UniprotIDQ5UAW9
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr1:9100792-9103480:-ENST00000377411.4ENSG00000180758.11GPR157UTR3AluYd8,AluJb,AluJr,AluSx,AluSq2chr1:9100792-9103480:-.alignment


Top

2. Tumor-specific enriched editing regions for GPR157


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr1:9100792-9103480:-BRCAEER1.8014e-17image
ENSG00000180758.11,GPR157BRCAEAG1.9111e-17image
chr1:9100792-9103480:-HNSCEER2.8676e-16image
ENSG00000180758.11,GPR157HNSCEAG2.9957e-16image
chr1:9100792-9103480:-KICHEER3.8620e-06image
ENSG00000180758.11,GPR157KICHEAG3.8620e-06image
chr1:9100792-9103480:-LIHCEER2.2327e-02image
ENSG00000180758.11,GPR157LIHCEAG2.2253e-02image
chr1:9100792-9103480:-LUSCEER8.9049e-07image
ENSG00000180758.11,GPR157LUSCEAG8.9821e-07image
chr1:9100792-9103480:-THCAEER4.4724e-02image
ENSG00000180758.11,GPR157THCAEAG4.4724e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000180758.11,GPR157BLCAPathEAG3.7648e-024.8345e-020.1000image
chr1:9100792-9103480:-BLCAPathEER3.7767e-024.9182e-020.0997image
chr1:9100792-9103480:-CESCCliEER6.8170e-047.3372e-05-0.2303image
ENSG00000180758.11,GPR157CESCCliEAG6.7894e-047.3548e-05-0.2303image
ENSG00000180758.11,GPR157ESCACliEAG1.6617e-023.7435e-02-0.2866image
chr1:9100792-9103480:-ESCACliEER1.7166e-023.8252e-02-0.2855image
ENSG00000180758.11,GPR157KIRPPathEAG1.0568e-041.2227e-050.3294image
chr1:9100792-9103480:-KIRPPathEER3.5497e-045.3808e-050.3063image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot
chr1:9100792-9103480:-LIHCEER2.3513e-021.5104e-021.3627e-01image
ENSG00000180758.11,GPR157LIHCEAG2.3513e-021.5340e-021.3712e-01image

Top

3. Enriched editing regions and immune related genes for GPR157


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:9100792-9103480:-BLCAEERENSG00000123240,OPTN0.44874.9447e-173.9667e-170.4091imageNHNRNPL;PTBP1OPTNT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE
chr1:9100792-9103480:-BLCAEERENSG00000204267,TAP20.44561.1426e-162.5326e-170.4114imageNPTBP1TAP2T_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:9100792-9103480:-BLCAEERENSG00000231925,TAPBP0.41045.5791e-144.8844e-170.4080imageNPTBP1TAPBPT_cells_CD4_memory_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:9100792-9103480:-BLCAEERENSG00000198721,ECI20.32441.1370e-082.0409e-170.4125imageNHNRNPL;PTBP1NAT_cells_CD4_memory_activatedGSVA_HALLMARK_DNA_REPAIR
chr1:9100792-9103480:-BLCAEERENSG00000165948,IFI27L10.32271.4567e-084.2661e-180.4205imageNHNRNPL;PTBP1IFI27L1T_cells_CD4_memory_activatedGSVA_HALLMARK_DNA_REPAIR
chr1:9100792-9103480:-BLCAEERENSG00000136280,CCM20.25401.6439e-052.9036e-170.4107imageNHNRNPL;PTBP1CCM2Macrophages_M2GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr1:9100792-9103480:-CESCEERENSG00000142089,IFITM30.45901.2705e-126.7846e-150.4321imageNPTBP1IFITM3T_cells_CD4_memory_restingGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:9100792-9103480:-CESCEERENSG00000240065,PSMB90.45141.0795e-114.1520e-140.4204imageNNPSMB9T_cells_CD8GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:9100792-9103480:-CESCEERENSG00000130303,BST20.44724.8749e-116.6308e-170.4600imageNPTBP1BST2B_cells_memoryGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:9100792-9103480:-CESCEERENSG00000225131,PSME2P20.43561.3879e-106.3075e-140.4177imageNNPSME2P2T_cells_CD8GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for GPR157


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr1:9100792-9103480:-
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.50711.0820e-203.8613e-18-0.4210imageNHNRNPL;PTBP1PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000180758.11,GPR157
BLCAEAGIRENSG00000205744.5chr196467206:6468118:6468233:6468327-0.31224.9610e-088.6419e-16-0.4106imageNADAR;BCCIP;CSTF2T;DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FUS;GTF2F1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;IGF2BP2;LIN28;LIN28B;NOP56;NOP58;PRPF8;SRSF7;TAF15;TARDBP;TROVE2;U2AF1;U2AF2;UPF1NADendritic_cells_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
ENSG00000180758.11,GPR157
BLCAEAGIRENSG00000100911.9chr1424145709:24145896:24146207:24146240-0.39095.1912e-123.4483e-16-0.4010imageNAUH;BCCIP;BUD13;CNBP;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;ZNF184PSME2T_cells_CD4_memory_activatedGSVA_HALLMARK_COMPLEMENT
chr1:9100792-9103480:-
BLCAEERIRENSG00000205744.5chr196467206:6468118:6468233:6468327-0.31233.5792e-088.6419e-16-0.4106imageNHNRNPLNADendritic_cells_activatedGSVA_HALLMARK_ALLOGRAFT_REJECTION
chr1:9100792-9103480:-
BLCAEERIRENSG00000100911.9chr1424145709:24145896:24146207:24146240-0.39093.6558e-123.5487e-16-0.4008imageNPTBP1PSME2T_cells_CD4_memory_activatedGSVA_HALLMARK_COMPLEMENT
ENSG00000180758.11,GPR157
BLCAEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.50681.2448e-204.4284e-18-0.4203imageNADAR;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;ZNF184PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr1:9100792-9103480:-
CESCEERIRENSG00000137965.6chr178659311:78661456:78662703:78662756-0.22872.8525e-031.2031e-10-0.4175imageNHNRNPL;PTBP1IFI44T_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr1:9100792-9103480:-
CESCEERA3ENSG00000163975.7chr3197006548:197007444:197003900:197004099:197003900:197004982-0.23834.2527e-033.7744e-13-0.4168imageNHNRNPL;PTBP1MFI2Macrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000180758.11,GPR157
CESCEAGIRENSG00000137965.6chr178659311:78661456:78662703:78662756-0.22862.6504e-031.2008e-10-0.4175imageNADAR;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPL;IGF2BP2;IGF2BP3;PTBP1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TROVE2;U2AF2;YTHDC1IFI44T_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000180758.11,GPR157
CESCEAGA3ENSG00000163975.7chr3197006548:197007444:197003900:197004099:197003900:197004982-0.23814.0171e-033.7880e-13-0.4167imageNADAR;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX54;DGCR8;DHX9;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;LARP7;LIN28;LIN28B;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RNF219;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TROVE2;U2AF1;U2AF2;UPF1;ZNF184MFI2Macrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

5. Enriched editing regions and immune infiltration for GPR157


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr1:9100792-9103480:-BLCAEERT_cells_CD4_memory_activated1.3826e-070.2632image
ENSG00000180758.11,GPR157BLCAEAGT_cells_CD4_memory_activated1.3971e-070.2631image
chr1:9100792-9103480:-BRCAEERT_cells_regulatory_(Tregs)3.0508e-040.1112image
ENSG00000180758.11,GPR157BRCAEAGT_cells_regulatory_(Tregs)3.2383e-040.1108image
chr1:9100792-9103480:-CESCEERT_cells_CD83.1084e-030.1713image
ENSG00000180758.11,GPR157CESCEAGT_cells_CD83.0791e-030.1715image
chr1:9100792-9103480:-CHOLEERNeutrophils1.3131e-020.4550image
ENSG00000180758.11,GPR157CHOLEAGNeutrophils1.3131e-020.4550image
chr1:9100792-9103480:-COADEERMacrophages_M11.5985e-040.2312image
ENSG00000180758.11,GPR157COADEAGDendritic_cells_activated3.5442e-030.1792image
chr1:9100792-9103480:-ESCAEERMacrophages_M23.0291e-020.1708image
ENSG00000180758.11,GPR157ESCAEAGMacrophages_M23.4059e-020.1672image
chr1:9100792-9103480:-GBMEERT_cells_CD4_memory_resting2.8633e-02-0.4563image
ENSG00000180758.11,GPR157GBMEAGT_cells_CD4_memory_resting2.8633e-02-0.4563image
chr1:9100792-9103480:-HNSCEERMacrophages_M14.4272e-050.1830image
ENSG00000180758.11,GPR157HNSCEAGMacrophages_M14.6271e-050.1826image
chr1:9100792-9103480:-KIRCEERT_cells_CD81.1099e-020.1487image
ENSG00000180758.11,GPR157KIRCEAGT_cells_CD81.1099e-020.1487image
chr1:9100792-9103480:-KIRPEERT_cells_gamma_delta1.3585e-030.2338image
ENSG00000180758.11,GPR157KIRPEAGT_cells_gamma_delta4.1436e-040.2563image
chr1:9100792-9103480:-LIHCEERT_cells_follicular_helper1.2726e-02-0.1418image
ENSG00000180758.11,GPR157LIHCEAGT_cells_follicular_helper1.2778e-02-0.1417image
chr1:9100792-9103480:-LUADEERB_cells_naive1.2520e-02-0.1132image
ENSG00000180758.11,GPR157LUADEAGB_cells_naive1.2494e-02-0.1132image
chr1:9100792-9103480:-LUSCEERT_cells_CD4_memory_activated4.7917e-040.1608image
ENSG00000180758.11,GPR157LUSCEAGT_cells_CD4_memory_activated4.8686e-040.1606image
chr1:9100792-9103480:-MESOEERMast_cells_resting4.0952e-02-0.2873image
ENSG00000180758.11,GPR157MESOEAGMast_cells_resting4.0952e-02-0.2873image
chr1:9100792-9103480:-OVEERT_cells_CD84.1487e-030.1724image
ENSG00000180758.11,GPR157OVEAGT_cells_CD83.9542e-030.1732image
chr1:9100792-9103480:-PAADEERMacrophages_M01.4464e-030.2460image
ENSG00000180758.11,GPR157PAADEAGMacrophages_M01.4508e-030.2460image
chr1:9100792-9103480:-PCPGEERT_cells_CD89.8513e-040.6080image
ENSG00000180758.11,GPR157PCPGEAGT_cells_CD89.8513e-040.6080image
chr1:9100792-9103480:-PRADEERPlasma_cells2.0219e-03-0.1433image
ENSG00000180758.11,GPR157PRADEAGPlasma_cells2.0219e-03-0.1433image
chr1:9100792-9103480:-READEERMacrophages_M22.1334e-020.2385image
ENSG00000180758.11,GPR157READEAGMacrophages_M22.1334e-020.2385image
chr1:9100792-9103480:-SARCEERT_cells_gamma_delta6.8435e-040.2673image
ENSG00000180758.11,GPR157SARCEAGT_cells_gamma_delta6.8533e-040.2673image
chr1:9100792-9103480:-SKCMEERMacrophages_M14.4180e-040.1762image
ENSG00000180758.11,GPR157SKCMEAGMacrophages_M14.7110e-040.1754image
chr1:9100792-9103480:-STADEERB_cells_memory6.1720e-03-0.1470image
ENSG00000180758.11,GPR157STADEAGT_cells_CD85.8281e-030.1480image
chr1:9100792-9103480:-TGCTEERB_cells_naive1.4266e-030.3406image
ENSG00000180758.11,GPR157TGCTEAGB_cells_naive1.4266e-030.3406image
chr1:9100792-9103480:-THCAEERMacrophages_M23.8196e-05-0.1872image
ENSG00000180758.11,GPR157THCAEAGMacrophages_M23.8196e-05-0.1872image
chr1:9100792-9103480:-UCECEERDendritic_cells_activated3.0573e-020.1732image
ENSG00000180758.11,GPR157UCECEAGDendritic_cells_activated4.2247e-020.1628image
chr1:9100792-9103480:-UCSEERT_cells_CD4_memory_resting8.4518e-03-0.3798image
ENSG00000180758.11,GPR157UCSEAGT_cells_CD4_memory_resting8.4518e-03-0.3798image


Top

6. Enriched editing regions and immune gene sets for GPR157


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr1:9100792-9103480:-BLCAEER5.2551e-03image4.0131e-080.2739image
ENSG00000180758.11,GPR157BLCAEAG5.2809e-03image4.2195e-080.2735image
chr1:9100792-9103480:-LIHCEER9.7094e-04image2.9950e-020.1237image
ENSG00000180758.11,GPR157LIHCEAG9.5739e-04image3.0339e-020.1234image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr1:9100792-9103480:-BLCAEER1.4916e-040.19111.8792e-030.15714.2844e-030.14456.0531e-060.2271image
ENSG00000180758.11,GPR157BLCAEAG1.5136e-040.19101.8660e-030.15724.2771e-030.14466.3726e-060.2266image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000180758.11,GPR157ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4869e-020.2822image
chr1:9100792-9103480:-ACCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4869e-020.2822image
chr1:9100792-9103480:-BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.7322e-160.4014image
ENSG00000180758.11,GPR157BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.9164e-160.4008image
ENSG00000180758.11,GPR157BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.4887e-130.2233image
chr1:9100792-9103480:-BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.0415e-130.2241image
chr1:9100792-9103480:-CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.9352e-110.3740image
ENSG00000180758.11,GPR157CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.1555e-110.3734image
ENSG00000180758.11,GPR157CHOLGSVA_HALLMARK_GLYCOLYSISEAG5.2825e-030.5043image
chr1:9100792-9103480:-CHOLGSVA_HALLMARK_GLYCOLYSISEER5.2825e-030.5043image
ENSG00000180758.11,GPR157COADGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG4.7699e-040.2139image
chr1:9100792-9103480:-COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.9164e-060.2757image
ENSG00000180758.11,GPR157DLBCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.6810e-030.4608image
chr1:9100792-9103480:-DLBCGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.6810e-030.4608image
ENSG00000180758.11,GPR157ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6734e-040.2924image
chr1:9100792-9103480:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5601e-040.2937image
chr1:9100792-9103480:-GBMGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEER4.5537e-02-0.4208image
ENSG00000180758.11,GPR157GBMGSVA_HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITIONEAG4.5537e-02-0.4208image
ENSG00000180758.11,GPR157HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.1065e-130.3146image
chr1:9100792-9103480:-HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.4802e-130.3158image
chr1:9100792-9103480:-KICHGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.2918e-02-0.3064image
ENSG00000180758.11,GPR157KICHGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG2.2918e-02-0.3064image
ENSG00000180758.11,GPR157KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0872e-030.1678image
chr1:9100792-9103480:-KIRCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0872e-030.1678image
chr1:9100792-9103480:-KIRPGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.5224e-040.2484image
ENSG00000180758.11,GPR157KIRPGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3672e-030.2331image
ENSG00000180758.11,GPR157LIHCGSVA_HALLMARK_COAGULATIONEAG6.8784e-050.2248image
chr1:9100792-9103480:-LIHCGSVA_HALLMARK_COAGULATIONEER7.0601e-050.2245image
ENSG00000180758.11,GPR157LUADGSVA_HALLMARK_UV_RESPONSE_UPEAG6.1391e-060.2035image
chr1:9100792-9103480:-LUADGSVA_HALLMARK_UV_RESPONSE_UPEER6.0760e-060.2036image
chr1:9100792-9103480:-LUSCGSVA_HALLMARK_E2F_TARGETSEER4.0825e-040.1627image
ENSG00000180758.11,GPR157LUSCGSVA_HALLMARK_E2F_TARGETSEAG4.1241e-040.1626image
ENSG00000180758.11,GPR157MESOGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG6.9181e-050.5277image
chr1:9100792-9103480:-MESOGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER6.9181e-050.5277image
ENSG00000180758.11,GPR157OVGSVA_HALLMARK_DNA_REPAIREAG2.0591e-050.2537image
chr1:9100792-9103480:-OVGSVA_HALLMARK_DNA_REPAIREER2.0998e-050.2535image
ENSG00000180758.11,GPR157PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2874e-030.2359image
chr1:9100792-9103480:-PAADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.2589e-030.2362image
chr1:9100792-9103480:-PCPGGSVA_HALLMARK_APICAL_SURFACEEER2.3377e-02-0.4431image
ENSG00000180758.11,GPR157PCPGGSVA_HALLMARK_APICAL_SURFACEEAG2.3377e-02-0.4431image
ENSG00000180758.11,GPR157PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG1.0285e-040.1797image
chr1:9100792-9103480:-PRADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER1.0285e-040.1797image
ENSG00000180758.11,GPR157READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.0556e-040.3912image
chr1:9100792-9103480:-READGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.0556e-040.3912image
ENSG00000180758.11,GPR157SARCGSVA_HALLMARK_MYC_TARGETS_V2EAG2.0541e-03-0.2435image
chr1:9100792-9103480:-SARCGSVA_HALLMARK_MYC_TARGETS_V2EER2.0848e-03-0.2431image
chr1:9100792-9103480:-SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.0075e-060.2258image
ENSG00000180758.11,GPR157SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG6.3837e-060.2252image
ENSG00000180758.11,GPR157STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1255e-110.3499image
chr1:9100792-9103480:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.3098e-110.3493image
chr1:9100792-9103480:-TGCTGSVA_HALLMARK_ANGIOGENESISEER3.5174e-05-0.4328image
ENSG00000180758.11,GPR157TGCTGSVA_HALLMARK_ANGIOGENESISEAG3.5174e-05-0.4328image
ENSG00000180758.11,GPR157THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG5.1819e-150.3475image
chr1:9100792-9103480:-THCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER5.1819e-150.3475image
chr1:9100792-9103480:-THYMGSVA_HALLMARK_PROTEIN_SECRETIONEER7.4803e-030.2584image
ENSG00000180758.11,GPR157THYMGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.4803e-030.2584image
chr1:9100792-9103480:-UCECGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.8485e-03-0.2474image
ENSG00000180758.11,GPR157UCECGSVA_HALLMARK_ANDROGEN_RESPONSEEAG4.5857e-03-0.2258image
ENSG00000180758.11,GPR157UCSGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG7.2817e-030.3865image
chr1:9100792-9103480:-UCSGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER7.2817e-030.3865image
ENSG00000180758.11,GPR157UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEAG1.8704e-020.4133image
chr1:9100792-9103480:-UVMGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.8704e-020.4133image


Top

7. Enriched editing regions and drugs for GPR157


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000180758.11,GPR157ACCABT.263EAG1.4491e-020.2832image
chr1:9100792-9103480:-ACCABT.263EER1.4491e-020.2832image
chr1:9100792-9103480:-BLCACGP.60474EER9.1917e-17-0.4047image
ENSG00000180758.11,GPR157BLCACGP.60474EAG1.0336e-16-0.4041image
ENSG00000180758.11,GPR157BRCAGNF.2EAG8.6559e-05-0.1208image
chr1:9100792-9103480:-BRCAGNF.2EER8.2581e-05-0.1212image
chr1:9100792-9103480:-CESCGDC.0449EER9.3737e-10-0.3461image
ENSG00000180758.11,GPR157CESCGDC.0449EAG9.2396e-10-0.3462image
ENSG00000180758.11,GPR157CHOLCCT007093EAG4.0534e-020.3826image
chr1:9100792-9103480:-CHOLCCT007093EER4.0534e-020.3826image
ENSG00000180758.11,GPR157COADBIRB.0796EAG4.2598e-050.2496image
chr1:9100792-9103480:-COADBIRB.0796EER1.7886e-050.2616image
ENSG00000180758.11,GPR157DLBCCCT007093EAG4.1397e-040.5573image
chr1:9100792-9103480:-DLBCCCT007093EER4.1397e-040.5573image
ENSG00000180758.11,GPR157ESCAAZ628EAG3.0594e-07-0.3904image
chr1:9100792-9103480:-ESCAAZ628EER3.4870e-07-0.3887image
chr1:9100792-9103480:-GBMBI.D1870EER2.4476e-02-0.4675image
ENSG00000180758.11,GPR157GBMBI.D1870EAG2.4476e-02-0.4675image
ENSG00000180758.11,GPR157HNSCFH535EAG3.3503e-110.2931image
chr1:9100792-9103480:-HNSCFH535EER3.1834e-110.2934image
chr1:9100792-9103480:-KICHBIBW2992EER1.3470e-020.3313image
ENSG00000180758.11,GPR157KICHBIBW2992EAG1.3470e-020.3313image
ENSG00000180758.11,GPR157KIRCCyclopamineEAG1.3964e-03-0.1865image
chr1:9100792-9103480:-KIRCCyclopamineEER1.3964e-03-0.1865image
chr1:9100792-9103480:-KIRPDasatinibEER1.7520e-03-0.2323image
ENSG00000180758.11,GPR157KIRPDasatinibEAG2.3469e-03-0.2254image
ENSG00000180758.11,GPR157LIHCAZD8055EAG4.5243e-04-0.1987image
chr1:9100792-9103480:-LIHCAZD8055EER4.8091e-04-0.1978image
ENSG00000180758.11,GPR157LUADBMS.509744EAG2.2224e-04-0.1667image
chr1:9100792-9103480:-LUADBMS.509744EER2.2407e-04-0.1666image
chr1:9100792-9103480:-LUSCGemcitabineEER3.3322e-04-0.1652image
ENSG00000180758.11,GPR157LUSCGemcitabineEAG3.4636e-04-0.1647image
ENSG00000180758.11,GPR157MESOBIRB.0796EAG3.0241e-030.4072image
chr1:9100792-9103480:-MESOBIRB.0796EER3.0241e-030.4072image
ENSG00000180758.11,GPR157OVCHIR.99021EAG7.0304e-080.3180image
chr1:9100792-9103480:-OVCHIR.99021EER7.1107e-080.3179image
ENSG00000180758.11,GPR157PAADCMKEAG1.0648e-02-0.1984image
chr1:9100792-9103480:-PAADCMKEER1.0572e-02-0.1986image
chr1:9100792-9103480:-PCPGMethotrexateEER1.4422e-02-0.4740image
ENSG00000180758.11,GPR157PCPGMethotrexateEAG1.4422e-02-0.4740image
ENSG00000180758.11,GPR157PRADGNF.2EAG1.8613e-02-0.1097image
chr1:9100792-9103480:-PRADGNF.2EER1.8613e-02-0.1097image
ENSG00000180758.11,GPR157READBIRB.0796EAG3.4189e-030.3006image
chr1:9100792-9103480:-READBIRB.0796EER3.4189e-030.3006image
ENSG00000180758.11,GPR157SARCDMOGEAG7.3086e-04-0.2660image
chr1:9100792-9103480:-SARCDMOGEER7.3366e-04-0.2659image
chr1:9100792-9103480:-SKCMErlotinibEER5.2130e-050.2029image
ENSG00000180758.11,GPR157SKCMErlotinibEAG5.2520e-050.2028image
ENSG00000180758.11,GPR157STADCI.1040EAG7.9079e-04-0.1796image
chr1:9100792-9103480:-STADCI.1040EER1.0066e-03-0.1761image
chr1:9100792-9103480:-TGCTCGP.60474EER1.7268e-070.5309image
ENSG00000180758.11,GPR157TGCTCGP.60474EAG1.7268e-070.5309image
ENSG00000180758.11,GPR157THCACI.1040EAG1.4026e-13-0.3296image
chr1:9100792-9103480:-THCACI.1040EER1.4026e-13-0.3296image
chr1:9100792-9103480:-THYMBMS.708163EER8.5237e-03-0.2543image
ENSG00000180758.11,GPR157THYMBMS.708163EAG8.5237e-03-0.2543image
chr1:9100792-9103480:-UCECBIBW2992EER1.4557e-030.2527image
ENSG00000180758.11,GPR157UCECBIBW2992EAG2.2222e-040.2915image
ENSG00000180758.11,GPR157UCSCisplatinEAG1.7312e-02-0.3457image
chr1:9100792-9103480:-UCSCisplatinEER1.7312e-02-0.3457image
ENSG00000180758.11,GPR157UVMAZD8055EAG1.1365e-020.4418image
chr1:9100792-9103480:-UVMAZD8055EER1.1365e-020.4418image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType